Fusobacterium Nucleatum Influence on Colorectal Cancer Dynamics

Fusobacterium nucleatum, an anaerobic bacterium commonly found in the oral cavity, has emerged as a key modulator of colorectal cancer (CRC) dynamics. Intratumoural enrichment of F. nucleatum correlates with increased tumour growth, recurrence, metastasis and poorer prognosis. Recent work has revealed that specific genetic lineages of this bacterium, notably a distinct clade termed Fna C2, are preferentially adapted to the colorectal niche, exhibiting enhanced adhesion, metabolic potential and evasion of immune surveillance. Mechanistically, F. nucleatum can activate pro-tumoural signalling cascades, induce chemoresistance by upregulating survival pathways and remodel the tumour microenvironment towards immunosuppression. Paradoxically, under certain conditions, it may also sensitise microsatellite-stable CRC to immune checkpoint blockade by generating metabolites that reinvigorate CD8+ T cells. Collectively, these findings highlight the global significance of F. nucleatum as both a biomarker and a therapeutic target in CRC management, paving the way for microbiota-centred diagnostic and treatment strategies.

Research from Nature Portfolio

Recent studies have delineated the genomic basis of F. nucleatum colonisation in CRC. Closed-genome sequencing of tumour-derived and oral strains uncovered over 400 genetic factors enriched in tumour isolates and identified two subspecies clades within Fna, with only the C2 lineage dominating CRC tissues. Functional analyses in murine models demonstrated that Fna C2 drives intestinal adenoma formation and alters local metabolite profiles. In parallel, foundational work has shown that the lectin Fap2 mediates specific binding to tumour-displayed Gal-GalNAc residues, facilitating bacterial infiltration, suppression of tumour-infiltrating lymphocytes and acceleration of metastatic progression. These insights into clade-specific pathoadaptation and adhesion mechanisms furnish precise molecular targets for disrupting tumour colonisation.

Fusobacterium Nucleatum Influence on Colorectal Cancer Dynamics publication trend

The graph below shows the total number of articles in fusobacterium nucleatum influence on colorectal cancer dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Clade: A group of organisms derived from a common ancestor, here referring to a subdivision of Fusobacterium nucleatum with distinct genetic traits.

Tumour microenvironment: The complex milieu of cells, signalling molecules and microorganisms surrounding cancer cells within a tumour.

Pathogen–tumour symbiont: A mutually beneficial relationship between a microbial pathogen and tumour cells that enhances tumour progression.

Nanozyme: A nanomaterial designed to mimic natural enzyme activity for catalytic therapeutic applications.

Microsatellite stable (MSS): Tumours lacking high levels of microsatellite instability, often less responsive to certain immunotherapies.

Chemoresistance: The capacity of cancer cells to withstand the cytotoxic effects of chemotherapy agents.

Fap2: A lectin expressed by Fusobacterium nucleatum that binds Gal-GalNAc residues on tumour cells to mediate adhesion and colonization.

References

1. Destroying pathogen-tumor symbionts synergizing with catalytic therapy of colorectal cancer by biomimetic protein-supported single-atom nanozyme. Signal Transduction and Targeted Therapy (2023).
2. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature (2024).
3. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell (2024).
4. Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges. Exploration (2023).
5. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nature Communications (2020).